A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer

"Preliminary steps : Safety Runs Safety run of the dual combination Durvalumab as single agent at the selected dose of 1500mg, every 4 weeks (Q4W) from C1D1 up to 13 doses~Safety run of the triple combination:~Durvalumab at 1500mg every 4 weeks (Q4W) from C1D1 up to 13 doses,~Efficacy step~* Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~* SBRT at C1D15, then~* Durvalumab Q4W alone for up to 9 additional doses"

"Preliminary steps : Safety Runs~Safety run of the triple combination:~Tremelimumab at 75mg/Q4W for up to 4 doses~Efficacy step~* Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~* SBRT at C1D15, then~* Durvalumab Q4W alone for up to 9 additional doses"

"Preliminary steps : Safety Runs~Safety run of the dual combination:~SBRT at C1D15.~Safety run of the triple combination:~SBRT at C1D15.~Efficacy step~* Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~* SBRT at C1D15, then~* Durvalumab Q4W alone for up to 9 additional doses"